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Introduction
The canonical pathway for homologous G protein-coupled receptor (GPCR) desensitization involves agonist activation of the receptor, subsequent G protein activation, G proteincoupled receptor kinase (GRK) translocation to the plasma membrane, phosphorylation of serine and threonine residues primarily on the C-terminal tail of the receptor by GRKs and arrestin binding to the phosphorylated receptor (Kelly et al., 2008) . While binding of arrestins to the receptor prevents further G protein activation (i.e. desensitizes the receptor-G proteincoupled effector activation pathway) it may also lead to arrestin-mediated signalling and receptor internalization, recycling and downregulation (Shenoy & Lefkowitz, 2011) .
In LC neurons taken from relatively mature animals DAMGO, a high efficacy MOPr agonist, induces substantial homologous MOPr desensitization (Llorente et al., 2012) . However, despite considerable effort there still remains controversy and confusion around the role of GRKs in the rapid desensitization of neuronal µ-opioid receptors (MOPrs) (for extensive review, see Williams et al., 2013) . Evidence in favour of a role of GRKs in neuronal MOPr desensitization by agonists with high intrinsic efficacy is threefold. First DAMGO-induced MOPr desensitization in rostral ventromedial medulla neurons was shown to be inhibited by intracellular perfusion of a GRK2 inhibitory peptide (Li and Wang, 2001 ). Second, fentanylinduced MOPr desensitization in the hippocampal dentate gyrus was absent in brain slices from GRK3 knockout (KO) mice (Terman et al., 2004) . Third, overexpression of a GRK2 dominant negative mutant (DNM) in rat LC neurons reduced DAMGO-induced MOPr desensitization (Bailey et al., 2009a) . On the other hand two studies have failed to provide evidence for any involvement of GRKs in MOPr desensitization. Neither heparin, a low affinity GRK inhibitor, nor staurosporine, a non-selective kinase inhibitor, had any effect on Met Enk-induced MOPr desensitization in rat LC neurons (Arttamangkul et al., 2012) . Also, using the GRK2as5 transgenic mouse in which GRK2 has been mutated to allow chemical inhibition it was observed that exposure to the inhibitor did not reduce Met Enk-induced desensitization in LC neurons (Quillinan et al., 2011) . However, this transgenic knockin/chemical inhibition approach would only inhibit GRK2 and not affect GRK3 or other GRKs.
Further complicating the issue, Dang et al., (2009) reported that in rat LC neurons both GRKs and ERKs were involved in MOPr desensitization; inhibition of GRK2/3 by intracellular dialysis of inhibitory peptides or ERK1/2 with a small molecule ERK1/2 activation inhibitor alone did not reduce Met Enk-induced desensitization but with concomitant inhibition of both types of kinase desensitization was inhibited.
In LC neurons in vitro morphine, an agonist with lower intrinsic efficacy (McPherson et al., 2010) , induced much less MOPr desensitization than high efficacy opioid agonists (Alvarez et al., 2002; Bailey et al., 2003) . The level of morphine-induced desensitization could be enhanced by concomitant activation of PKC either indirectly by stimulation of Gq-coupled M 3 muscarinic receptors or directly with a phorbol ester (Bailey et al., 2004) . Expression of the GRK2 DNM did not prevent PKC-mediated MOPr desensitization on morphine application (Bailey et al., 2009a) . In contrast, in hippocampal dentate gyrus GRK3 knockout reduced morphine-induced desensitization (Terman et al., 2004) .
Until very recently there have been no small molecule selective, membrane permeable inhibitors of GRKs. In this paper we have examined the effects of a novel small molecule inhibitor of GRK2 and GRK3, Takeda Compound 101 (Cmpd101) Thal et al., 2011) , as well as GRK3 knockout and signalling kinase inhibitors on the rapid desensitization of the MOPr-activated inwardly rectifying potassium current (GIRK) in LC neurons. We have sought to address several questions relating to the role of GRKs in MOPr desensitization. First, are GRK2 and GRK3 involved in the acute MOPr desensitization induced by high intrinsic efficacy agonists, arrestin-biased agonists and lower intrinsic efficacy agonists? Second, do both GRK2 and GRK3 play a role in MOPr desensitization? 
Whole-cell path-clamp recording
Slices were submerged in a slice chamber (Warner Instruments, Hamden CT, USA) mounted on a microscope stage (BX51WI, Olympus, Southend-on-Sea, UK) and superfused (2.5 -3 ml/min) with aCSF at 33 o C. LC neurons were visualized using Nomarski optics using infrared light. Whole-cell patch clamp recordings were made using electrodes (3-6 MΩ) filled with (in mM): 115 K-methylsulfonate, 10 NaCl, 2 MgCl 2 , 10 HEPES, 6 EGTA, 2
MgATP, and 0.5 Na 2 GTP (pH 7.25, osmolarity 270 mOsm responses were studied, noradrenaline (NA) was applied in the presence of prazosin (1 µM) and cocaine (3 µM). Because GIRK currents were much smaller in mouse LC, responses in mice were measured in the presence of the glutamate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 µM) and the GABA A receptor antagonist bicuculline (10 µM) to inhibit spontaneous excitatory and inhibitory postsynaptic currents.
Cell culture
Human embryonic kidney 293 cells (HEK 293) cells stably over expressing haemagglutinintagged rat MOPr (HA-MOPr) were cultured at 37 °C in 5% CO 2 in Dulbecco's modified Eagles's medium (DMEM) supplemented with 10 % fetal bovine serum, 10 U/ml penicillin, 10 mg/ml streptomycin (Invitrogen, Life Technologies, Paisley UK) and 250 µg/ml G418 (Merck, Nottingham, UK). Cells were seeded onto 60 mm dishes and grown to 90 % confluence then subjected to serum starvation for 24 h.
WGA-enrichment of HA-MOPr
Glycosylated HA-MOPr was enriched from cells that were lysed in pull down buffer (PDB) composed of (in mM) 20 HEPES [pH 7.4], 150 NaCl, 1 Na 3 VO 4 , 10 β -glycerophosphate, 50
NaF, 1 PMSF and 5 EDTA plus 1% Triton X-100, 10% glycerol, 0.1% SDS, 2 µg/ml leupeptin, 2 µg/ml aprotinin and 1 µg/ml pepstatin A. Densitometry of bands was undertaken using ImageJ (NIH, USA), duplicate values were taken for each sample and then averaged. pSer 375 levels were normalized against corresponding total HA-MOPr levels and pERK1/2 against total ERK1/2 levels determined in the same experiment.
Internalization Assays
DAMGO-induced internalization of HA-MOPr was assessed by ELISA as previously described (Johnson et al., 2006) and by confocal microscopy imaging (Mundell et al., 2006) .
HEK 293 cells stably expressing HA-MOPr were prelabelled with primary antibody for 1 h at 4 °C before incubation with Cmpd101 (3 or 30 µM) for 30 min at 37 °C. Cells were then stimulated with DAMGO (10 µM) at 37 °C to induce internalization. In the ELISA changes in surface receptor expression were subsequently determined by normalizing data from each treatment group to corresponding control surface receptor levels determined from cells not exposed to DAMGO in the same experiment. For confocal imaging cells were imaged using a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DM16000
inverted epifluorescence microscope with a pLApoBL 63 x oil immersion objective.
Arrestin Translocation Assay
For the arrestin-3 recruitment assay, PathHunter TM cells and accompanying assay kit were obtained from DiscoveRx (Birmingham, UK). These cells are U2OS (human osteosarcoma) 1 2 cells stably expressing tagged human MOPr and tagged arrestin-3 such that recruitment of arrestin-3 to the receptor leads to reconstitution of β -galactosidase activity which is measured by luminescence in a plate reader (McPherson et al., 2010) . The experiments were undertaken exactly as described in the manufacturer's instructions, with the agonist DAMGO being added to the cells for 90 min, and where applicable Cmpd101 being added alone or 30 min before DAMGO.
Kinase Screen
The express kinase screen was performed at the Medical Research Council International
Centre for Kinase Profiling (Dundee, UK). The screen was comprised of 52 human enzymes providing a representative sampling of the kinome, with the exception of lipid kinases. The method used was a radioactive filter binding assay using 32 ATP which provides a direct measure of kinase activity (Hastie et al., 2006; Bain et al., 2007) . Cmpd101 was studied at a concentration of 1 µM. Results are given as the percentage of kinase activity in the absence of the inhibitor. The ATP concentrations used were at or below the calculated K m for ATP for each individual kinase. The screen was performed in duplicate and results are given as a mean value with standard deviation.
Quantification of DAMGO-induced loss of functional MOPr
Following desensitization of MOPr by bath-application of DAMGO, DAMGO was replaced by morphine. Using the operational model of agonism (Black et al., 1985) , transducer ratio (tau) values for morphine were calculated (as in Bailey et al., 2009b) . Percentage loss of receptor responsiveness (f) was then calculated using the equation f = 100 x (1 -tau2/tau1) where tau1 is the value in control slices and tau2 is the value after DAMGO-induced desensitization (Lohse et al., 1990) .
Statistics
Data are presented as means ± standard errors and were analysed by unpaired two-tailed Student's t-tests, one-way or two-way ANOVA with Bonferroni post-hoc test as appropriate using Prism5 (Graphpad Software Inc., San Diego CA, USA). Differences were assumed to be significant at P<0.05.
Drugs and compounds
benzamidehydrochloride (Cmpd101 hydrochloride) was synthesized at the University of Bath (Bath, UK) in 9 steps from isonicotinic acid hydrazide . Analysis of the final compound (as the free base) provided data consistent with the structure with purity >99% (by 13 δ 167.6, 153.8, 153.2, 150.3, 147.5, 136.6, 135.2, 134.4, 132.3, 130.2, 129.5, 128.1, 127.8, 127.5, 126.0, 125.9, 125.8, 125.7, 123.1, 122.5, 116.6, 116.3, 111.9, 76.7, 40.5, 39.3, 31.6 , ESIMS: calc. for C 24 H 21 F 3 N 6 NaO, 489.1627; found 489.1701. 
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RESULTS
Role of GRK2 and GRK3 in acute MOPr desensitization induced by Met Enk or
DAMGO.
In rat LC neurons, activation of MOPrs by receptor-saturating concentrations of Met Enk (30 µM), DAMGO (10 µM) or endomorphin-2 (10 µM) elicited outward current through GIRK channels that rapidly desensitized in the presence of the drug, with only about 50% of the initial current remaining after 10 min exposure ( Fig. 1) . To examine the role of GRK2 and GRK3 in the Met Enk-induced desensitization, LC slices were pre-treated with the inhibitor, Cmpd101, at concentrations previously shown to inhibit desensitization of β 2 adrenoceptors in HEK 293 cells . Cmpd101 concentration-dependently reduced the amount of Met Enk-induced desensitization ( Neither the ERK1/2 nor JNK inhibitor applied on its own in the absence of Cmpd 101
affected Met Enk-induced desensitization (Control: 51 ± 6%, n=5; + 10 µM PD98059: 43 ± 5%, n=5; + 30 µM SP600125: 50 ± 4%, n=5). Amlexanox has recently been identified as a GRK5 inhibitor (Homan et al., 2014b) . When cells were exposed to Cmpd101 and amlexanox (50 µM) there was no further reduction in desensitization compared with Cmpd101 alone (Fig. 1C ). Amlexanox applied on its own in the absence of Cmpd101 did not affect Met Enk-induced desensitization (% Met Enk-induced desensitization in 50 µM amlexanox alone: 51 ± 3%, n=5).
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The inhibition of MOPr desensitization that we observed with Cmpd101 does not appear to be due to it acting as a MOPr antagonist to reduce the number of receptors being activated.
When a submaximal concentration of Met Enk (600nM) was applied before and following exposure of cells to Cmpd101 (3 µM for 15 min), the Met Enk response in the presence of Cmpd101 was not different from the initial response before Cmpd101 (94 ± 13% of initial response, n=4, one-sample t-test vs. 100%, p>0.05).
Role of GRK2 and GRK3 in morphine-induced MOPr desensitization
Although morphine produces much less acute MOPr desensitization in LC neurons compared to either Met Enk or DAMGO (Bailey et al., 2004; 2009a) , the morphine response did desensitize by about 25% over a 15 min application (Fig. 1J-L) . Pre-treatment with Cmpd101 (30 µM) significantly reduced the morphine-induced desensitization. This suggests that GRK2 and GRK3 are not only involved in desensitization to higher efficacy MOPr agonists such as Met Enk and DAMGO, but are also involved in desensitization to the partial agonist morphine in the absence of PKC activation.
MOPr desensitization in LC neurons from GRK3 knockout mice
Cmpd101 was previously shown to be almost equally effective at inhibiting GRK2 and GRK3 (Thal et al., 2011) . GRK3 KO has been reported to abolish the desensitization induced by fentanyl and morphine in rat hippocampal dentate gyrus neurons (Terman et al., 2004) . To determine whether GRK3 was the sole isoform required for MOPr desensitization in LC neurons, we measured Met Enk-induced desensitization in LC neurons prepared from GRK3 KO mice. The amplitude of the Met Enk-induced current was similar in neurons from both GRK3 KO and wild type (WT) mice (WT: 72 ± 10 pA, n=6; GRK KO: 58 ± 11 pA, n=6, p>0.05). Met Enk-induced desensitization measured after 10 min of Met Enk application was also not significantly different in GRK3 KO neurons compared to WT controls ( Fig. 2A-B ). To ensure that there was not a species-specific difference in the mechanism of desensitization,
we also examined the ability of Cmpd101 to inhibit Met Enk-induced desensitization in mouse LC neurons since the previous experiments with Cmpd101 were performed in rat LC neurons. In LC neurons from C57Bl/6J WT mice, Met Enk produced a similar amount of desensitization (45%) to that observed in rat neurons after a 10 min application. Cmpd101
inhibited the Met Enk-induced desensitization in WT mouse LC neurons, being maximally effective at the lower (3 µM) concentration (Fig. 2C-D) .
These results suggest first that GRK2 plays a role in Met Enk-induced desensitization in LC neurons and second, either that GRK3 plays no role in Met Enk-induced desensitization in LC neurons or that GRK3 is not solely responsible. However, as Cmpd101 is a mixed GRK2/3 inhibitor, we cannot exclude the possibility that both GRK2 and GRK3 are involved and that removal of only one (in our current experiments GRK3) is insufficient to inhibit desensitization.
Loss of functional MOPrs underlying acute MOPr desensitization
There is a significant MOPr reserve in LC neurons, that needs to be removed (i.e. desensitized) before any decrease in the response to a supramaximal concentration of a full agonist such as Met Enk or DAMGO can be detected and therefore the true proportion of receptors that have been desensitized is hard to assess from responses such as those shown in Fig. 1 (Connor et al., 2004) . To determine the actual loss of functional MOPrs following desensitization we used a previously developed protocol that measures the decrease induced by desensitization of the maximum response to the partial agonist morphine (Bailey et al., 2009b) . For a partial agonist, the maximum response occurs when all the receptors are occupied and therefore any decrease in maximum response is directly related to a loss of receptor function. To be able to compare results from different neurons, the morphine response in each was normalized to the response to noradrenaline (NA, 100 µM), which activates α 2 ARs that couple to the same pool of GIRKs in LC neurons (North and Williams, 1985) .
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In control LC neurons the maximum response evoked by morphine was 85% of the maximum response to NA (100 µM) (Fig. 3A) . To examine the reduction in morphine response caused by DAMGO-induced MOPr desensitization, neurons were first treated with DAMGO (10 µM) for 12 min to induce desensitization, then the maximum response to morphine (30 µM) was determined at plateau (6 mins after DAMGO was replaced by morphine; Fig. 3B & C) . In neurons that were first treated with DAMGO (10 µM) for 12 min to induce desensitization the maximum response to morphine was reduced by over 80% (Fig.   3B ). Using the operational model of agonism (Black et al., 1985) to estimate the actual loss of functional MOPrs induced by DAMGO (for details see Bailey et al., 2009b and Methods section) we calculate that the DAMGO treatment induced a 93% loss of functional MOPrs.
When we repeated the experiment but this time in the presence of Cmpd101 (3 or 30 µM) the desensitization induced by DAMGO was markedly reduced as was the reduction in the maximum response to morphine (Fig. 3C & D) . In the presence of 30 µM Cmpd101 the desensitization induced by DAMGO (10 µM) reduced the maximum response to morphine by only 44% which equates to a 59% loss of functional MOPrs. Thus whilst Cmpd101 reduced the DAMGO-induced loss of functional receptors from 93 to 59% this reduction was sufficient to produce a marked reduction in the desensitization observed during application of a receptor-saturating concentration of agonist (Fig. 1 ).
Overall our findings with Cmpd101 suggest that GRK2 and possibly also GRK3 are involved in both Met Enk-and DAMGO-induced desensitization of MOPr, but it is clear that there is a component of desensitization that still remains in the presence of the drug either because of incomplete inhibition of GRK2 and GRK3 by Cmpd101 or because an additional Cmpd101-resistant mechanism of desensitization exists. Translocation of arrestin3 to agonist-activated MOPr was assessed using the DiscoveRx PathHunter R assay. Application of DAMGO (10 µM for 90min) led to a large recruitment of arrestin3 to MOPr which was dramatically reduced by in the presence of Cmpd101 (30 µM) (Fig. 4C ).
MOPr phosphorylation, internalization and arrestin translocation
We assessed internalization of HA-tagged MOPrs by ELISA and confocal microscopy using an anti-HA antibody to label surface receptors. DAMGO (10 µM) application induced MOPr internalization in a time-dependent manner and Cmpd101 markedly reduced DAMGOinduced MOPr internalization (Fig. 4D& E ).
These data demonstrate that Cmpd101 was able to block DAMGO-induced MOPr phosphorylation on Ser 375 , arrestin recruitment, and MOPr internalization presumably by inhibiting GRK2 and GRK3. This contrasts somewhat with our data from LC neurons where although Cmpd101 could reduce agonist-induced desensitization the extent of the reduction was only about 34% when calculated as loss of functional receptors.
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ERK1/2 phosphorylation
It has previously been reported that GRK2 and GRK3 inhibition alone was not sufficient to inhibit Met Enk-induced desensitization in mouse LC neurons but that a combination of GRK2, GRK3 and ERK1/2 inhibition was required i.e. there was overlap and redundancy between GRK and ERK1/2 in MOPr desensitization (Dang et al., 2009 ). To confirm that Cmpd101 did not inhibit ERK1/2 activity, we measured both the phosphorylation of ERK1/2, which is often used as a measure of its activity (Roskoski, 2012) and the phosphorylation of Elk-1 by ERK1/2 (Cruzalegui et al., 1999) in HEK 293 cells stably expressing HA-tagged MOPrs. Cmpd101 did not affect the DAMGO-induced (10 µM, 5 min) increase in ERK1/2 phosphorylation ( Fig. 5A & B) . Moreover, at 30 µM Cmpd101 on its own produced a small increase in basal ERK1/2 phosphorylation ( Fig. 5A & B) . Similarly, Cmpd101 (30 µM) did not inhibit the DAMGO-induced (10 µM, 5 min) increase in Elk-1 phosphorylation ( Fig. 5C &   D) . The ERK1/2 activation inhibitor, PD98059, significantly decreased both DAMGO-induced ERK1/2 and Elk-1 phosphorylation (Fig. 5E) .
Thus, the ability of Cmpd101 to decrease MOPr desensitization in the LC is unlikely to be due to an inhibition of ERK1/2 activity in combination with the inhibition of GRK activity.
Selectivity of kinase inhibition by Cmpd101
Cmpd101 has previously been shown to be highly selective for GRK2 and GRK3 over other GRK isoforms Thal et al., 2011) . We subjected Cmpd101 to a further kinase screen at the Medical Research Council International Centre for Kinase Profiling (Dundee, UK) to determine whether it inhibited the activity of other non-GRK kinases. As this screen was conducted on purified kinases in vitro we performed the screen using 1 µM Cmpd101 (i.e. 30x the reported IC 50 for inhibition of GRK2 in in vitro purified enzyme assay conditions Figure 1 ). Cmpd101 inhibited only 5 off-target kinases by more than 50%; these included protein kinase C related protein kinase (PRK2) and serum and glucocorticoid regulated kinase (SGK1) which were inhibited by 93% and 69% respectively. To test whether either of these kinases might be involved in DAMGO-induced desensitization, we pre-treated rat LC slices with established inhibitors of these kinases. GSK650394 (10 µM) is an inhibitor of SGK1 and Y-27632 (50 µM) is an inhibitor of both PRK2 and ROCK2 which Cmpd101 also inhibited by 47% in the kinase screen. LC neurons pre-treated with a combination of these two kinase inhibitors did not show any difference in the amount of desensitization induced by a 10 min application of DAMGO (30 µM) compared to that observed in control neurons (Supplementary Figure 2) .
Therefore, these off target actions of Cmpd101 do not appear to play a role in the inhibition of MOPr desensitization by Cmpd101. 1
Discussion
We have studied the effects of Cmpd101, a novel membrane permeable, small molecule inhibitor of both GRK2 and GRK3 on agonist-induced MOPr desensitization in LC neurons.
Cmpd101 has previously been reported to be a potent inhibitor of GRK2 and GRK3, with reported IC 50 values of 35 nM Other approaches previously taken to inhibit GRKs include the broad spectrum kinase inhibitor, staurosporine (Arttamangkul et al., 2012) , the PKC/GRK inhibitor Ro32-0432 (Hull et al., 2010) , 'β-ARK-1 inhibitor' (Iino et al., 2002; Hull et al., 2010) and the antidepressant drug paroxetine (Thal et al., 2012; Homan et al., 2014a) . However, none of these approaches combine the cell-permeable, potency and selectivity profiles of
Cmpd101. Moreover, Cmpd101 shows specificity between GRK2/3 and GRK5. Across a range of opioid agonists with different intrinsic efficacies for G protein activation (Met Enk, DAMGO and morphine) and arrestin bias (endomorphin 2) we observed that Cmpd101 reduced the desensitization of the opioid-activated GIRK current indicating the involvement of GRK2 and/or GRK3 in this desensitization. The effective concentrations of Cmpd101 in these whole cell assays was 100 -1000 fold higher than the concentrations that inhibit GRK2 and GRK3 in vitro. This likely results from low permeability of the molecule across the MOL #98293
2 2 cell membrane but could also be due to other factors such as differences in the conformation or properties of the kinases in a cellular environment.
Our observation that MOPr desensitization in LC neurons was unaffected by GRK3 knockout indicates that in these neurons GRK3 is not solely responsible for MOPr desensitization. GRK2as5 transgenic mouse has also been reported not to affect Met Enk-induced desensitization in LC neurons (Quillinan et al., 2011) . Further, although overexpression of a GRK2 dominant negative mutant (DNM) reduced DAMGO-induced MOPr desensitization in rat LC neurons (Bailey et al., 2009a) , this DNM construct is likely to also inhibit GRK3, based on homology of the GRK2 and GRK3 isoforms. Given that Cmpd101 is a potent inhibitor of both GRK2 and GRK3 our data suggest that in LC neurons there is an overlap and redundancy of GRK2 and GRK3 such that KO of only one (e.g. GRK3) is insufficient to inhibit desensitization. phosphorylates Ser 375 in the C-terminal tail in vitro (Chen et al., 2012 phosphorylate several amino acid residues in the C-terminal tail of MOPr (Doll et al., 2011 (Doll et al., , 2012 Just et al., 2013 ) are subsequently phosphorylated in a hierarchical manner. This higher-order phosphorylation has been shown to be mediated by GRK2 and GRK3 in that it is reduced by siRNA knockdown of these GRK isoforms. currently unidentified, but it does not involve ERK1/2, PKC or JNK as in the present study inhibitors of these kinases did not reduce MOPr desensitization further in the presence of Cmpd101. One potential alternative mechanism for the residual component of MOPr desensitization is that catalytically-inactive GRK2/3 binds β γ subunits of the G-protein, inhibiting GIRK channel function (Raveh et al., 2010) , while we cannot rule this out previous work suggests that this process does not play a role in rat LC neurons of this age (Llorente et al., 2012) . Of the other GRK subtypes expressed in mammalian neurons (GRK5 and GRK6), our data suggest that GRK5 is not responsible, as the GRK5 inhibitor, amlexanox, was ineffective. Although amlexanox lacks specificity (Reilly et al., 2013) , and we have no direct proof that it is permeating LC neurons in the slice, it has been shown to inhibit intracellular GRK5-mediated responses, with near complete block at 50 µM (Homan et al., 2014b ). It is not currently known if amlexanox also inhibits the structurally-similar GRK6, although previous studies (Bailey et al., 2009b) have shown no effect of GRK6 on MOPr desensitization using viral-transfection of dominant negative mutant GRK6.
We have been unable to obtain any evidence to support the view that ERK1/2 participate in MOPr desensitization as proposed by Dang et al., (2009) . In our preliminary in vitro kinase screen Cmpd101 did show some inhibition of both ERK1 and ERK2 but this was modest (20% inhibition) with a concentration of Cmpd101 that would inhibit GRK2 by over 90%.
However we found no evidence in intact cells that Cmpd101 could decrease ERK1/2 phosphorylation or inhibit the phosphorylation of Elk-1 by ERK1/2. Thus we have excluded the possibility that Cmpd101 inhibits MOPr desensitization by inhibiting both GRK2/3 and ERK1/2.
In conclusion, we demonstrate that Cmpd101 offers a simple means to study the roles of GRK2/3 in GPCR desensitization and other cellular functions. We show here that a component of MOPr desensitization in rodent LC neurons is GRK2/3-mediated. Data from GRK3 knockout mice demonstrate that GRK3 ablation alone is insufficient to inhibit MOPr desensitization in these neurons, suggesting either a selective role for GRK2, or, redundancy of action between GRK2 and GRK3. The development of a membranepermeable, small-molecule inhibitor of GRK2/3 gives the opportunity to explore the roles of these kinases in desensitization of MOPRs, and other GPCRs, in native tissues and in vivo.
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